A team of researchers led by Fred Hutchinson Cancer Research Center has identified a new mechanism that explains why some recurrent ovarian tumors become resistant to treatment with commonly used platinum-based chemotherapy drugs such as cisplatin and carboplatin. They describe their research online Feb. 10 in the journal Nature.
A team of researchers led by Fred Hutchinson Cancer Research Center has identified a new mechanism that explains why some recurrent ovarian tumors become resistant to treatment with commonly used platinum-based chemotherapy drugs such as cisplatin and carboplatin. They describe their research online Feb. 10 in the journal Nature.
A series of genes that protect cells from the powerful, common chemotherapeutic agent doxorubicin has been identified by researchers working to understand how the drug also can destroy the heart.
Development of a rash after treatment with inhibitors of epidermal growth factor receptor (EGFR) such as Tarceva (erlotinib) may actually indicate that the treatment is working well, according to an analysis of two phase III trials.
Chemotherapy
